Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

about

The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population.

P2860

Q50936603-28102866-CAD4-43F6-A60C-3BFF59D84F05

P2860

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

Item

http://www.wikidata.org/entity/Q58835397

description

scientific article published on 10 February 2013

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2013

@uk

name

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@en

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@nl

type

Item

label

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@en

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@nl

prefLabel

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@en

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@nl

P1476

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

@en

P2093

Avelino Fraga

http://www.w3.org/2001/XMLSchema#string

Joaquina Maurício

http://www.w3.org/2001/XMLSchema#string

Marta Velho Sousa

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular alterations during progression of prostate cancer to androgen independence

The development of androgen-independent prostate cancer

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Redefining hormone resistance in prostate cancer.

A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

Prospective study of sex hormone levels and risk of prostate cancer.

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer

An update on androgen deprivation therapy for prostate cancer.

P2888

s12032-013-0490-2

P304

490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-013-0490-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rui Medeiros

Ricardo Ribeiro

Cátia Monteiro

P577

2013-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23397084

http://www.w3.org/2001/XMLSchema#string

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

about

P2860

P2860

Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698